Manufacturers start developing their trade names for a new drug during which of the following drug approval phases?
A) Clinical phase 1 trials
B) Clinical phase 2 trials
C) Clinical phase 3 trials
D) Phase IV
A) Clinical phase 1 trials
In Clinical Phase 1 trials, manufacturers start developing their trade name for a
new drug. Dosages and adverse effects are assessed on approximately 20-100 human volunteers
initially, who have the disease or condition that the drug is being tested to treat. Doses are often
subtherapeutic, but ascending (increasing) doses are used.
You might also like to view...
Do not ________ a reconstituted solution of Factor VIII
Fill in the blank(s) with correct word
The short period of electrical inactivity between the end of the P wave and the start of the QRS complex is called the:
A) P pause. B) PR segment. C) PR interval. D) PR pause.
Medical insurance specialists use practice management programs to
A. record payments from insurance companies. B. schedule patients. C. collect data on patients' diagnoses and services. D. All of these are correct.
The Fair Debt Collection Practices Act (FDCPA) does not cover which type of debts?
A) business B) personal C) family D) household